Apricus Biosciences, Inc. (NASDAQ:APRI) reported Revenues for the quarter ended June 30, 2015 were $0.5 million, compared to revenue of $5.5 million in the second quarter of 2014. Revenues in the second quarter of 2014 were primarily related to the recognition of revenues associated with the out-licensing of Vitaros in certain European territories, including France and Spain, with Majorelle and Recordati, respectively. Apricus Biosciences, Inc. (NASDAQ:APRI) belongs to Healthcare sector. Its weekly performance is -12.75%. On last trading day company shares ended up $1.30. Apricus Biosciences, Inc. (NASDAQ:APRI) distance from 50-day simple moving average (SMA50) is -21.54%.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), announced that it will report its unaudited financial results for the second quarter ended June 30, 2015 on Thursday, August 6, 2015, after the U.S. financial markets close. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares decreased -0.21% in last trading session and ended the day at $47.60. ACAD return on assets is -40.00%. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) quarterly performance is 29.45%.
Christopher D. Myers, President and Chief Executive Officer of CVB Financial Corp., (NASDAQ:CVBF) made a presentation and hosting one-on-one meetings with investors at the 16th Annual Keefe, Bruyette & Woods Community Bank Investor Conference on Tuesday, July 28, 2015. The conference took place at the Grand Hyatt in New York City, NY from July 28 to July 29, 2015. On 05 August, CVB Financial Corp. (NASDAQ:CVBF) shares increased 0.45% and was closed at $17.82. CVBF EPS growth in last 5 year was 11.80%. CVB Financial Corp. (NASDAQ:CVBF) year to date (YTD) performance is 12.87%.
Morgan Stanley upgraded shares of Jumei International Holding (NYSE:JMEI) from an underweight rating to an equal weight rating in a research report released on Monday morning, TheFlyOnTheWall.com reports. Jumei International Holding Limited (NYSE:JMEI) ended the last trading day at $18.72. Company weekly volatility is calculated as 6.18% and price to cash ratio as 4.68. Jumei International Holding Limited (NYSE:JMEI) showed a weekly performance of 3.65%.
Dermira, Inc. (NASDAQ:DERM) announced the pricing of its follow-on public offering of 4,500,000 shares of its common stock at a price to the public of $21.50 per share. In addition, Dermira has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock, on the same terms and conditions. Dermira, Inc. (NASDAQ:DERM) shares decreased -1.69% in last trading session and ended the day at $22.08. DERM return on assets is -35.50%. Dermira, Inc. (NASDAQ:DERM) quarterly performance is 50.51%.